Ashley Diaz-Granados was appointed as Managing Director of Eli Lilly and Company, Northern Europe in December 2018, having moved to the UK in early 2017 to lead Lilly Diabetes in Northern Europe. Ashley is passionate about great leadership, a mentor to numerous employees and an active diversity and inclusion advocate. Ashley has a bachelor’s degree in social work (Columbia); a Master’s degree in social work (Washington), and completed Harvard Business School’s Advanced Management programme.
Ashley has held a number of senior leadership roles at Lilly, including leading the US Integrated Health function, working to gain access in managed care organisations, pharmacy management companies, government programmes, physician practices and hospitals. Ashley’s prior career included leading a 150-strong sales team, Training and Development, and Six Sigma, where she became a certified black belt.
Jyun Yan Yang
Jyun-Yan (Jeff) Yang is the Senior Medical Director for the Lilly Northern European Hub. Jeff has been with Lilly for more than 10 years and served as the medical director for the Taiwan affiliate, Asia Operations region and global Emgality team. Before coming to UK, Jeff was the Global Brand Development leader for the migraine platform, developing and commercialising novel migraine treatments around the world. Prior to Lilly, Jeff had over 15 years of experience in healthcare management consulting, pharmaceutical development and clinical medicine.
Jeff received his Doctor of Medicine degree from Kaohsiung Medical University in Taiwan. He earned a Master of Science degree in Health Policy and Management from Harvard School of Public Health and received the Charles F. Wilinsky Award for Academic Excellence. He recently co-authored manuscripts which were published in the journals of Cephalalgia, Headache, and New England Journal of Medicine.
Sue Forda is Vice President, International Regulatory Affairs, Eli Lilly and Company. She is responsible for all International regulatory aspects of Lilly’s portfolio for new and existing products. Sue is also Managing Director of the Eli Lilly UK Research and Development office.
Sue has contributed to trade association activities for many years and is a member of EFPIA’s Innovation Board Steering Committee and a member of EFPIA’s Regulatory Strategy Committee. She is also a member of the ICH management committee.
Sue trained as a pharmacist. After completing a PhD in neuropharmacology, she worked as a post-doctoral research fellow at the University of London.